Skip to content
Getting-Hitched-05 (2)

ResApp Health Ltd (ASX: RAP) received a $100m takeover offer from Pfizer

ResApp Health Ltd (ASX: RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has entered into a binding scheme implementation deed with Pfizer Australia Holdings Pty Ltd (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company), under which it proposed that Pfizer Inc, will acquire 100% of the shares in ResApp Health by way of a Scheme of Arrangement for A$0.115/share in cash, representing a total equity value of approximately A$100m. ResApp CEO and managing director Tony Keating said ‘We are excited by the prospect of this acquisition by Pfizer, a leading biopharmaceutical company that shares our vision and belief that technology can help transform healthcare and improve patients’ lives.

Following the announcement, shares of ResApp Ltd traded 22.22% hjgher at $0.11/share.

See more stories like this

    Your Cart
    Your cart is emptyReturn to Shop
      Apply Coupon